Triple-negative breast cancer: epidemiological considerations and recommendationsBOYLE, P.Annals of oncology. 2012, Vol 23, issn 0923-7534, vi7-vi12, SUP6Article

Locoregional treatments for triple-negative breast cancerEIERMANN, W; VALLIS, K. A.Annals of oncology. 2012, Vol 23, issn 0923-7534, vi30-vi34, SUP6Article

Neoadjuvant treatments for triple-negative breast cancer (TNBC)VON MINCKWITZ, G; MARTIN, M.Annals of oncology. 2012, Vol 23, issn 0923-7534, vi35-vi39, SUP6Article

Imaging of triple-negative breast cancerDOGAN, B. E; TURNBULL, L. W.Annals of oncology. 2012, Vol 23, issn 0923-7534, vi23-vi29, SUP6Article

Understanding the biology of triple-negative breast cancerCRISCITIELLO, C; AZIM, H. A; SCHOUTEN, P. C et al.Annals of oncology. 2012, Vol 23, issn 0923-7534, vi13-vi18, SUP6Article

Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracilCOLLEONI, M; PRICE, K. N; CASTIGLIONE-GERTSCH, M et al.Lancet (British edition). 1999, Vol 354, Num 9173, pp 130-131, issn 0140-6736Article

Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancerWALLGREN, A; BERNIER, J; GELBER, R. D et al.International journal of radiation oncology, biology, physics. 1996, Vol 35, Num 4, pp 649-659, issn 0360-3016Article

Premenopausal endocrine-responsive early breast cancer : who receives chemotherapy?REGAN, M. M; PAGANI, O; CASTIGLIONE-GERTSCH, M et al.Annals of oncology. 2008, Vol 19, Num 7, pp 1231-1241, issn 0923-7534, 11 p.Article

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)PESTALOZZI, B. C; ZAHRIEH, D; SIMONCINI, E et al.Annals of oncology. 2006, Vol 17, Num 6, pp 935-944, issn 0923-7534, 10 p.Article

Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer : role of endocrine responsiveness of the tumorCOLLEONI, M; LI, S; PAGANI, O et al.Annals of oncology. 2005, Vol 16, Num 5, pp 716-725, issn 0923-7534, 10 p.Article

Factors affecting baseline quality of life in two international adjuvant breast cancer trialsBERNHARD, J; HÜRNY, C; GOLDHIRSCH, A et al.British journal of cancer. 1998, Vol 78, Num 5, pp 686-693, issn 0007-0920Article

Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancerHÜRNY, C; BERNHARD, J; GOLDHIRSCH, A et al.Lancet (British edition). 1996, Vol 347, Num 9011, pp 1279-1284, issn 0140-6736Article

Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancerGRUBER, G; COLE, B. F; FEV, M. F et al.Annals of oncology. 2008, Vol 19, Num 8, pp 1393-1401, issn 0923-7534, 9 p.Article

Risk factors for locoregional recurrence among breast Cancer patients: Results from international breast Cancer Study Group trials I through VIIWALLGREN, A; BONETTI, M; FORBES, J. F et al.Journal of clinical oncology. 2003, Vol 21, Num 7, pp 1205-1213, issn 0732-183X, 9 p.Article

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancerCOLLEONI, M; PRICE, K; CASTIGLIONE-GERTSCH, M et al.European journal of cancer (1990). 1998, Vol 34, Num 11, pp 1693-1700, issn 0959-8049Article

Prognostic importance of thymidylate synthase expression in early breast cancerPESTALOZZI, B. C; PETERSON, H. F; GOLOUH, R et al.Journal of clinical oncology. 1997, Vol 15, Num 5, pp 1923-1931, issn 0732-183XArticle

Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerVIALE, G; GIOBBIE-HURDER, A; PRICE, K. N et al.Annals of oncology. 2010, Vol 21, Num 2, pp 245-254, issn 0923-7534, 10 p.Article

Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experienceBERCLAZ, G; LI, S; SNYDER, R et al.Annals of oncology. 2004, Vol 15, Num 6, pp 875-884, issn 0923-7534, 10 p.Article

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer : The International Breast Cancer Study Group Trial VIICRIVELLARI, D; BONETTI, M; LINDTNER, J et al.Journal of clinical oncology. 2000, Vol 18, Num 7, pp 1412-1422, issn 0732-183XArticle

Defining clinical benefit in postmenopausal patients with breast Cancer under second-line endocrine treatment : Does quality of life matter?BERNHARD, J; THÜRLIMANN, B; SCHMITZ, S.-F. H et al.Journal of clinical oncology. 1999, Vol 17, Num 6, pp 1672-1679, issn 0732-183XArticle

Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen : Formestane versus megestrol acetate as second-line hormonal treatmentBERNHARD, J; CASTIGLIONE-GERTSCH, M; SCHMITZ, S.-F. H et al.European journal of cancer (1990). 1999, Vol 35, Num 6, pp 913-920, issn 0959-8049Article

Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapyCASTIGLIONE-GERTSCH, M; TATTERSALL, M; SENN, H.-J et al.European journal of cancer (1990). 1997, Vol 33, Num 14, pp 2321-2325, issn 0959-8049Article

The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-upCASTIGLIONE-GERTSCH, M; JOHNSON, C; SIMPSON, J et al.Annals of oncology. 1994, Vol 5, Num 8, pp 717-724, issn 0923-7534Article

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancerBERNHARD, J; ZAHRIEH, D; GREEN, M. D et al.British journal of cancer. 2008, Vol 98, Num 1, pp 25-33, issn 0007-0920, 9 p.Article

Hormone replacement and breast cancerCASTIGLIONE-GERTSCH, M.Annals of oncology. 2004, Vol 15, pp iv275-iv277, issn 0923-7534, SUP4Conference Paper